Recent news on Goserelin

Ambrilia Announces Closing of $5.5 Million Private Placement  -  May 18, 2007
SYS-CON Media,..."This injection of funds will serve in accelerating Ambrilia's HIV Integrase Inhibitor Program as well as moving Octreotide and Goserelin closer to the

Luteinising-Hormone-Releasing Hormone Agonists May Be Effective ...  -  May 21, 2007
Cancer Consultants (press release),Combined endocrine treatment with Zoladex® (goserelin) and tamoxifen has been shown to be equivalent to CMF for premenopausal HR+ patients in some trials.

New hormone treatments can fight certain breast cancers  -  May 21, 2007
Pharma Times (subscription),LHRH agonists like AstraZeneca's drug Zoladex (goserelin) switch off the ovary and stop the production of the female hormone oestrogen, which can encourage

Women could avoid chemotherapy with hormone drug  -  May 18, 2007
New Scientist (subscription),Another follow-up treatment is a "luteinising hormone-releasing hormone (LHRH) agonist", which includes drugs such as leuprolide and goserelin.

Ovarian Suppression Has Role in Premenopausal Breast Cancer Therapy  -  May 18, 2007
MedPage Today,Previous studies have looked at the effects of LHRH agonists such as goserelin (Zoladex) or leuprorelin (Lupron) alone or in combination with tamoxifen and

Chemo-free cancer cure 'will save thousands'  -  May 17, 2007
Daily Mail,Drugs such as Zoladex, also known as goserelin, were originally developed to treat prostate cancer. They have been used against breast cancer for some years

Ambrilia Announces Conference Call and Webcast Details for First ...  -  May 8, 2007
Genetic Engineering News (press release),...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

EAU 2007 - Step-Up to CAB May Prolong PSA Response in Patients ...  -  Mar 29, 2007
UroToday,Importantly, addition of bicalutamide 50 mg was associated with very little additional morbidity in patients already receiving goserelin.

Study Shows Ambrilia's Therapeutic Peptide PCK3145 Has Clinical ...  -  Apr 24, 2007
PipelineReview.com (press release),...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

Ambrilia Announces Fiscal 2006 Results  -  Mar 27, 2007
CCNMatthews (press release),..."We also plan to initiate a phase 1/2 single dose study in hormone-sensitive prostate cancer patients with Ambrilia's new formulation of Goserelin.

Ambrilia Announces the Appointment of Stephen G. Sudovar as ...  -  Apr 18, 2007
SYS-CON Media,...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

Mixing Adjuvant Therapies Prolongs Early Breast Cancer Survival  -  Apr 4, 2007
Psychiatric Times,The hormone agonists used were 3.6 mg of goserelin (Zoladex) and 3.75 mg of leuprorelin acetate (Lupron). Neither is FDA approved for the treatment of early

Breast cancer therapies' side effects vary by age  -  Feb 20, 2007
Scientific AmericanPast research has found that for some premenopausal women, breast cancer treatment with standard chemotherapy or a hormonal therapy with goserelin is

Men With Prostate Cancer More Optimistic After Several Years of ...  -  Feb 21, 2007
Drug Newswire (press release),The most commonly used therapy in the men surveyed was the hormonal treatment ZOLADEX (goserelin), which this year celebrates 20 years since its first

Ambrilia Announces Election of New Chairman and Appointment of New ...  -  Jan 30, 2007
Genetic Engineering News (press release),...a Tumor Vasculature Targeting (TVT) technology platform, two improved formulations of existing drugs (Octreotide and Goserelin) developed with a

Treatment-Induced Amenorrhea May Prevent Breast Cancer Relapse ...  -  Dec 20, 2006
DG NewsFollowing surgery, the women were randomized to 1 of 2 treatment regimens: 1) ovarian suppression with 3.6 mg of goserelin (Zoladex) every 28 days for 3

Prostrate Cancer Treatment Affects Penile Length  -  Jan 11, 2007
MedIndia,These patients were studied over a period of 5 years when they were receiving three doses of leuprolide or goserelin injections once in three months.

Young breast cancer patients test super-hormone treatment  -  Dec 26, 2006
Wilkes Barre Times-Leader,The drugs include triptorelin, goserelin, leuprolide and buserelin, sold as Lupron, Zoladex, Prostap and other brands. Such drugs have been around for 20

Young breast cancer patients test super-hormone treatment  -  26 Dec 2006
Wilkes Barre Times-Leader,The drugs include triptorelin, goserelin, leuprolide and buserelin, sold as Lupron, Zoladex, Prostap and other brands. Such drugs have been around for 20

Treatment-Induced Amenorrhea: Adverse Effect or Benefit? - San ...  -  Dec 16, 2006
PR Newswire (press release),Goserelin specifically suppresses the function of the ovaries, including the production of estrogen. Patients receiving standard chemotherapy received 6

Prescribing Inconsistencies In Prostate Cancer Treatment In The UK ...  -  Dec 17, 2006
Medical News Today (press release),Zoladex (goserelin) is licensed for all stages of prostate cancer suitable for hormonal manipulation.[2] Also, it is the only LHRHa with a proven survival

Treatment-Induced Amenorrhea May Prevent Breast Cancer Relapse ...  -  Dec 20, 2006
DG NewsFollowing surgery, the women were randomized to 1 of 2 treatment regimens: 1) ovarian suppression with 3.6 mg of goserelin (Zoladex) every 28 days for 3

Study Evaluates Quality of Life and Menstrual Function in ...  -  Dec 13, 2006
Cancer Consultants (press release),Zoladex® (goserelin) is a medication known as a leuteinizing hormone releasing hormone (LHRH) agonist. In women Zoladex suppresses hormone production by the

SABCS: Amenorrhea During Treatment Helps Breast Cancer Prognosis  -  Dec 18, 2006
MedPage Today,After surgery, they were randomized to ovarian ablation with 3.6 mg of Zoladex (goserelin) every 28 days for three years and 20 mg of tamoxifen daily for

Super-hormone treatments could reduce risk of recurrence  -  Dec 18, 2006
NewsOK.com (subscription),The drugs include triptorelin, goserelin, leuprolide and buserelin, sold as Lupron, Zoladex, Prostap and other brands.

Cancer patients test new treatment  -  Dec 17, 2006
Houston Chronicle,The drugs include triptorelin, goserelin, leuprolide and buserelin. Such drugs have been around for 20 years and are used more in Europe than in the United

Drug-induced menopause may save lives  -  Dec 18, 2006
Charlotte Observer,The drugs include triptorelin, goserelin, leuprolide and buserelin. Such drugs have been around for 20 years and are used more in Europe than in the US,

Hormones used in breast Cancer fight  -  Dec 17, 2006
El Paso Times,...goserelin, leuprolide and buserelin, sold as Lupron, Zoladex, Prostap and other brands. Such drugs have been around for 20 years and are used more in Europe

Zometa® Prevents Bone Loss in Premenopausal Breast Cancer Patients  -  Dec 14, 2006
Cancer Consultants (press release),Drugs known as leuteinizing hormone releasing hormone (LHRH) agonists, such as Zoladex® (goserelin), suppress hormone production by the ovaries.

Ambrilia Announces that Phase 1 Study Results Support Continued ...  -  Dec 8, 2006
Genetic Engineering News (press release),...a new formulation of Goserelin, promising anti-HIV treatments (PPL-100, HIV Integrase Inhibitor Program), other anti-virals and immunomodulators.

Aggressive Treatment of PSA Recurrences After Primary Treatment Is ...  -  Dec 6, 2006
Cancer Consultants (press release),They were treated with 4 cycles of Taxotere and Emcyt followed by Zoladex® (goserelin) or Casodex® (bicalutamide) for 15 months. The main findings of this

Ambrilia to Host Third Quarter 2006 Results Conference Call  09 Nov 2006
...an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of ... -Market Wire (press release) Additional hormone therapy use after radiation for some prostate ...  Nov 6, 2006
Everyone received approximately four months of hormone therapy (goserelin and flutamide) before and during their radiation treatments. ... -EurekAlert (press release), Prostate Cancer Hormone Therapy May Have Unwelcome Side Effects  Oct 30, 2006
...agonists. Common drugs in this class include leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), and triptorelin (Trelstar). ... -ACS News Center, Ambrilia to Present at UBS Global Life Sciences Conference in New ...  Sep 19, 2006
...includes an anti-cancer therapeutic peptide (PCK3145), a novel anticancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first ... -PharmaLive.com

Researchers from the United Kingdom, Canada and Poland detail new ...  Sep 7, 2006
Study 1: Breast cancer treatment is enhanced by the addition of goserelin to standard adjuvant therapy. According to scientists ... -Therapeutics Daily (subscription)

Low PSA After Androgen Deprivation Therapy Linked with Improved ...  Aug 29, 2006
The initial course of androgen deprivation therapy consisted of seven months of Zoladex® (goserelin) and Casodex® (bicalutamide). ... -Cancer Consultants

How to Manage Hot Flashes as a Cancer Patient  Sep 1, 2006
...patients on hormonal therapy – Men may experience hot flashes if they take drugs such as Lupron Depot ® (leuprolide) or Zoladex ® (goserelin) to reduce ... -CancerWise

Prescribing inconsistencies in prostate cancer treatment in the UK ...  -  12 Dec 2006
EurekAlert (press release),Zoladex (goserelin) is licensed for all stages of prostate cancer suitable for hormonal manipulation.[2] Also, it is the only LHRHa with a proven survival

New Research Calls for Reclassification of Zoladex as Curative  -  Nov 13, 2006
UroToday,The researchers conclude that adjuvant goserelin should be reclassified as a treatment of ‘curative’ intent for men with poor prognosis, non-metastatic

Ambrilia Announces that Phase 1 Study Results Support Continued ...  -  Dec 8, 2006
Genetic Engineering News (press release),...a new formulation of Goserelin, promising anti-HIV treatments (PPL-100, HIV Integrase Inhibitor Program), other anti-virals and immunomodulators.

Aggressive Treatment of PSA Recurrences After Primary Treatment Is ...  -  Dec 6, 2006
Cancer Consultants (press release),They were treated with 4 cycles of Taxotere and Emcyt followed by Zoladex® (goserelin) or Casodex® (bicalutamide) for 15 months. The main findings of this

Ambrilia Announces Third Quarter 2006 Results and Provides Update ...  -  Nov 14, 2006
CCNMatthews (press release),Goserelin, Ambrilia's specialty generic for the treatment of hormone-sensitive prostate cancer, is the potential first-to-market equivalent of Astra

Women With Early Breast Cancer are More Likely to Remain Cancer ...  -  Nov 16, 2006
campus med,...'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed) and 'IRESSA' (gefitinib) as well as a range of novel targeted products such as anti-proliferatives,

Ambrilia Announces European Licensing Partnership with TEVA for ...  -  Nov 16, 2006
PipelineReview.com (press release),...an improved, prolonged release formulation of Octreotide, a new formulation of Goserelin and promising anti-HIV treatments (PPL-100, Anti-HIV Peptides,

APS: New Research Calls for Reclassification of ZOLADEX as Curative  -  Nov 13, 2006
ANP Pers Support,The researchers reviewed goserelin as it is the. of more than five years. From these findings, the researchers assessed whether the

Ambrilia Appoints Mr. Luc Tanguay to its Board of Directors  Aug 22, 2006
...an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of ... -Market Wire

Doctors Investigate Treatment of Men’s Breast Cancer  Jul 31, 2006
...oncologist who specializes in breast cancer, said her goal is to find out if a pill called "anastrozole" and a synthetic hormone called "goserelin" can lower a ... -13WHAM-TV

Ambrilia Announces Second Quarter 2006 Results and Provides Update ...  Aug 10, 2006
Goserelin, Ambrilia's specialty generic for the treatment of hormone-sensitive prostate cancer, is the equivalent of Astra Zeneca's Zoladex®. ... -Market Wire

Biovail Reports Second-Quarter 2006 Financial Results; Company ...  Aug 10, 2006
LP entered into an agreement pursuant to which BPI's specialty sales force began promotional activities for Zoladex(R) 3.6mg (goserelin acetate implant) to ... -Genetic Engineering News

Ambrilia Announces Second Quarter 2006 Results and Provides Update ...  Aug 10, 2006
Goserelin, Ambrilia's specialty generic for the treatment of hormone-sensitive prostate cancer, is the equivalent of Astra Zeneca's Zoladex ® . ... -CCNMatthews

Goserelin-Induced New-Onset Depressive Disorder  Jul 14, 2006
TO THE EDITOR: We report a case of new-onset depressive disorder in a patient with a documented history of prostate cancer treated with goserelin and no ... -Psychosomatics (subscription)

Combination of anastrozole and a synthetic hormone called ...  Jul 10, 2006
By treating male breast cancer with a combination of anastrozole and a synthetic hormone called goserelin, Nahleh believes physicians may be able to stop the ... -News-Medical.net

Local Doctors Testing New Breast Cancer Treatments  Jul 20, 2006
Her goal is to find out if a pill called Anastrozole and a synthetic hormone called Goserelin can lower a man's overall estrogen levels and limit breast tumor ... -WKRC 12

Pharmac funds lift less than inflation  Jul 20, 2006
...this financial year it had added a new long-acting insulin for diabetes (Lantus) and widened access to treatments for prostate cancer (goserelin) and asthma ... -Stuff.co.nz



Biovail to Promote AstraZeneca's Zoladex(R) 3.6mg (Goserelin ...  May 2, 2006
...and AstraZeneca Pharmaceuticals LP have entered into an agreement for which BPI's specialty sales force will promote Zoladex(R) 3.6mg (goserelin acetate implant ... - Genetic Engineering News

Prostate Cancer: EAU Highlights on Recent Findings  May 11, 2006
Mulders and colleagues [12] state in their abstract that, depending on the definitions used, adjuvant goserelin should be classified as a therapy of curative ... - Medscape (subscription)

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
...product portfolio includes mid to early-stage products (PPL-100, PCK3145, TVT-Dox, SPC3) and two specialty generics (Octreotide and Goserelin), the first of ... - Genetic Engineering News

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Goserelin, Ambrilia's specialty generic for the treatment of hormone-sensitive prostate cancer, is the equivalent of Astra Zeneca's Zoladex® and was acquired ... - Market Wire

Ambrilia to Host First Quarter 2006 Results Conference Call  May 4, 2006
...promising anti-HIV treatments (PPL-100, SPC3), a tumor vasculature targeting technology (TVT-Dox) and two specialty generics (Octreotide, Goserelin), the first ... - CCNMatthews

Addition of Zoladex® to Standard Therapy May Benefit ...  Apr 28, 2006
Among premenopausal women with early breast cancer, the addition of Zoladex® (goserelin) to adjuvant treatment with radiation therapy and/or chemotherapy ... - Cancer Consultants

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Goserelin, Ambrilia's specialty generic for the treatment of hormone-sensitive prostate cancer, is the equivalent of Astra Zeneca's Zoladex ® and was acquired ... - CCNMatthews

Addition of Zoladex® to Standard Therapy May Benefit ...  May 4, 2006
Researchers affiliated with the Zoladex in Pre-Menopausal Patients (ZIPP) study have reported that the addition of Zoladex® (goserelin) to adjuvant treatment ... - Cancer Consultants

Boosting cells could lead to enhanced pain releif  Apr 20, 2006
...disease. These include morphine, for pain relief, Clozapine for schizophrenia and Goserelin for breast and prostate cancers. The ... - Times Online

BREAST CANCER: THE MIRACLE DRUGS TRUTH  Apr 28, 2006
Nice.". UNLIKE most of the new drugs, Zoladex (goserelin) is suitable for use by premenopausal women with oestrogen-sensitive cancers. ... - Mirror.co.uk





Ambrilia Announces Term Extension of Investissement Quebec's ...  Apr 7, 2006
The second generic product is a sustained-release formulation of Goserelin, used primarily for the treatment of hormone-sensitive prostate cancer. ... - CCNMatthews

New research in the area of cancer therapy detailed  Apr 6, 2006
...therapy data. Study 1: Premature menopause may be averted with goserelin given before and during chemotherapy. "Standard methods ... - Therapeutics Daily (subscription)

Ambrilia Announces Fiscal 2005 Results and Appointment of Three ...  Mar 22, 2006
The second product is a sustained-release formulation of Goserelin, used primarily in hormone-sensitive prostate cancer, and is expected to be launched in ... - Genetic Engineering News

New Data Show Zometa Increased Bone Mineral Density in Breast ...  Mar 22, 2006
...inhibitor associated bone loss in premenopausal women with hormone-responsive breast cancer receiving combination endocrine treatment (goserelin and tamoxifen ... - PharmaLive.com



Procyon Announces the Completion of the Acquisition of Cellpep SA ...  Mar 1, 2006
The second product, Goserelin, is expected to be launched in Europe in 2008. With these late-stage products, Ambrilia Biopharma ... - PharmaLive.com,

Gonadotropin-Releasing Hormone Anologue Prevents Ovarian Failure ...  Feb 8, 2006
Researchers from Italy have reported that the administration of the gonadotropin releasing hormone analogue goserelin (Gn-RH) prevents ovarian failure in women ... - Cancer Consultants

Procyon Presents Preclinical Results with its Novel Tumor ...  Feb 7, 2006
The second product, goserelin, is expected to be launched in Europe in 2008. With this combined portfolio comprised of high-value ... - CCNMatthews

Ovarian Suppression During Chemotherapy May Protect Ovarian ...  Jan 27, 2006
...first dose of the GnRH analogue. The GnRH analogue used in this study was Zoladex® (goserelin). Patients enrolled at the beginning ... - Cancer Consultants

Procyon Biopharma to Acquire Cellpep SA  Jan 19, 2006
Cellpep is also developing goserelin, an improved version of a prostate cancer drug as well as a fusion inhibitor for HIV and several other peptides. ... - TechFinance

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional